Gregory D Cuny

This inventor holds 69 USPTO granted patents and 17 published patent applications, plus 3 CIPO patents and 7 EPO patents, primarily in Protein Kinase Inhibitors. Top assignees: The Brigham and Women's Hospital, Inc., Sepracor, Inc., Harvard College. Active years: 1997-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gregory D Cuny. Retrieved from https://idiyas.com/inventor/gregory-d-cuny

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 69 (Patent Applications = 17)

% Patents Active = 79.7

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 20)

Average Co-Inventor Count = 5.1

ph-index = 17

Forward Citations = 681(Granted Patents)

Forward Citations (Not Self Cited) = 618(Dec 10, 2025)

Location History:

Woodbury, MN (US) (1997 - 2003)
Hudson, MA (US) (2000 - 2006)
Somerville, MA (US) (2004 - 2015)
Cambridge, MA (US) (2015)
Houston, TX (US) (2013 - 2024)

Company Filing History:

31 out of 1,429

The Brigham and Women's Hospital, Inc.

3M Innovative Properties Company

patents

6. 5 out of 276

Massachusetts Eye and Ear Infirmary

patents

7. 5 out of 619

University of Houston System

patents

8. 4 out of 3,076

The General Hospital Corporation

Dana-Farber-Cancer Institute Inc.

patents

11. 3 out of 3,697

The United States of America, as Represented by the Secretary, Department of Health and Human Services

University of Georgia Research Foundation Inc

patents

15. 2 out of 2

Yuma Therapeutics, Inc.

patents

16. 1 out of 2

Aquinnah Pharmaceuticals, Inc.

patents

17. 1 out of 3,363

Chinese Academy of Sciences

The Ohio State University

patents

where one patent can have more than one assignee

Years Active: 1997-2024

Loading Chart...

Areas of Expertise:

Protein Kinase

Atoh1 Expression

BMP Inhibitors

Gastrointestinal Infections

USP1 Deubiquitinating Enzyme

Pyrimidine Compounds

Indoles

Heterocyclic Inhibitors

Necroptosis

Ligands

Stereoselective Synthesis

TDP-43 Inclusions

69 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12012402 - Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases (2024-06-18),

2. 11174255 - Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases (2021-11-16),

3. 11160808 - Compounds that enhance Atoh1 expression (2021-11-02),

4. 11135209 - Compositions and methods for inhibiting protein kinases (2021-10-05),

5. 10961254 - Pyrimidine compounds and methods using the same (2021-03-30),

6. 10653676 - Small molecule inhibitors of USP1 deubiquitinating enzyme activity (2020-05-19),

7. 10513521 - Compositions and methods for inhibiting BMP (2019-12-24),

8. 10406163 - Compounds that enhance Atoh1 expression (2019-09-10),

9. 10336768 - Pyrimidine compounds and methods using the same (2019-07-02),

10. 10125116 - Compounds and methods for treating mammalian gastrointestinal microbial infections (2018-11-13),

11. 10017516 - BMP inhibitors and methods of use thereof (2018-07-10),

12. 9725452 - Substituted indoles and pyrroles as RIP kinase inhibitors (2017-08-08),

13. 9682983 - BMP inhibitors and methods of use thereof (2017-06-20),

14. 9556129 - Phosphatidylcholine transfer protein inhibitors (2017-01-31),

15. 9518032 - Small molecule inhibitors of USP1 deubiquitinating enzyme activity (2016-12-13),

Title: Innovations by Gregory D. Cuny in Pharmaceutical Chemistry

Introduction

Gregory D. Cuny, a prolific inventor based in Somerville, MA, is known for his significant contributions to the field of pharmaceutical chemistry. With a remarkable portfolio of 38 patents, Cuny’s work primarily focuses on developing innovative compounds aimed at treating various health disorders, particularly those related to obesity and necroptosis.

Latest Patents

Among Gregory D. Cuny's latest patents are groundbreaking inventions involving phosphatidylcholine transfer protein inhibitors and heterocyclic inhibitors of necroptosis. The first invention discusses compounds represented by Formulas I, II, and III, which serve as inhibitors of phosphatidylcholine transfer protein (PC-TP). This work addresses pharmaceutical compositions and therapeutic methods targeting disorders associated with obesity through the inhibition of PC-TP.

The second patent highlights a series of heterocyclic derivatives designed to inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. These compounds, detailed in Formulas (I) and (Ia)-(Ie), have been shown to inhibit necroptosis in FADD-deficient human Jurkat T cells. This innovative approach could pave the way for new treatments where necroptosis plays a significant role, showcasing Cuny's dedication to advancing medical science.

Career Highlights

Gregory D. Cuny has worked with prominent organizations, including Sepracor, Inc. and Brigham and Women's Hospital. His tenure at these institutions has provided him with valuable experience and insight into the pharmaceutical industry, which has undoubtedly influenced his prolific inventorship.

Collaborations

Throughout his career, Gregory D. Cuny has collaborated with talented professionals, including James R. Hauske and Brian M. Aquila. These partnerships have fostered innovative research and development efforts, leading to the successful creation of numerous impactful patents in the field.

Conclusion

Gregory D. Cuny’s innovative work and extensive patent portfolio demonstrate his significant impact on pharmaceutical advancements. His inventions hold promise for developing treatments to combat obesity and related disorders, along with other health issues where necroptosis is a critical factor. Cuny’s dedication to research and collaboration continues to inspire future innovations in the field of pharmaceutical chemistry.

Profile summary based on public USPTO records.